The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia

[+] Article, Author, and Disclosure Information

Grant support: in part by grants HL29074 and HL32271 by the General Clinical Research Centers Program (RR334), U. S. Public Health Service. Dr. lllingworth is the recipient of a Research Career Development Award (HL00953) from the National Institutes of Health.

Presented in part in November 1983 at the 56th Scientific Meeting of the American Heart Association, Anaheim, California [Abstract in Circulation. 1983;68(4 pt 2):III-188].

▸Requests for reprints should be addressed to D. Roger lllingworth, M.D., Ph.D.; Department of Medicine—L465, Oregon Health Sciences University; Portland, OR 97201.

Portland, Oregon

©1984 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1984;101(5):598-604. doi:10.7326/0003-4819-101-5-598
Text Size: A A A

Twelve patients with severe heterozygous familial hypercholesterolemia, in whom other hypolipidemic drug therapy had failed to reduce serum cholesterol levels to less than 300 mg/dL, were sequentially treated with mevinolin (a specific inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis) and colestipol. In ten patients receiving 80 mg/d of mevinolin, plasma cholesterol concentrations decreased 33%, from 487 ± 27 (SE) mg/dL to 326 ± 16 mg/dL. Additional therapy with colestipol resulted in a further 18% decrease, to 269 ± 13 mg/dL. Concentrations of low density lipoprotein (LDL) cholesterol decreased in parallel (54% decrease on combined drug therapy). Plasma concentrations of high density lipoprotein cholesterol did not change significantly, but the LDL:HDL ratio decreased from 8.2 in patients on diet only to 3.8 in patients treated with mevinolin and colestipol. In seven patients treated with 40 mg/d of mevinolin, concentrations of LDL cholesterol decreased by 33%; combined therapy resulted in a further 20% decrease (46% reduction from the level achieved with diet only). No consistent side effects have been noted in up to 24 months of therapy. Combined therapy with mevinolin and colestipol promises to be effective for heterozygous familial hypercholesterolemia.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Journal Club
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.